Mcp

Metoclopramide, the active ingredient in Mcp, is a dopamine D2 receptor antagonist presented as an oral tablet for oral use. It treats nausea and vomiting, gastroparesis and gastroesophageal reflux disease in adult patients.

GNH USA supplies Mcp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each batch, ensuring reliable access for healthcare providers across multiple regions. Our distribution network includes major hospital systems, community pharmacies and specialty clinics, facilitating timely delivery and support.

Metoclopramide is used to manage conditions involving nausea, vomiting and impaired gastrointestinal motility.

Nausea and vomiting: reduces episodes by blocking dopamine receptors in the chemoreceptor trigger zone, improving comfort in adults. Gastroparesis: enhances gastric emptying by increasing gastrointestinal motility, helping patients achieve better nutrient absorption. Gastroesophageal reflux disease: alleviates reflux symptoms through prokinetic action, decreasing acid exposure in the esophagus.

Metoclopramide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness: mild sedation or fatigue. - Diarrhea: loose stools or increased bowel movements. - Restlessness: feeling of inner tension or agitation. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Extrapyramidal symptoms: muscle rigidity, tremor or dystonia, especially with high doses. - Tardive dyskinesia: irreversible involuntary movements with prolonged use. - Neuroleptic malignant syndrome: rare life‑threatening condition with fever and muscle rigidity. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Before prescribing Metoclopramide, clinicians should consider several safety precautions. - Assess renal function: dose adjustment may be needed in patients with renal impairment. - Limit duration: avoid use beyond 12 weeks to reduce risk of tardive dyskinesia. - Monitor for depression: watch for worsening mood or suicidal thoughts. - Avoid in patients with gastrointestinal obstruction: drug may exacerbate blockage. - Caution in the elderly: increased susceptibility to central nervous system side effects. - Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Metoclopramide can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Anticholinergic agents: may reduce prokinetic effect and increase anticholinergic side effects. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): can raise metoclopramide plasma levels, increasing toxicity risk. - Dopamine antagonists (e.g., antipsychotics): additive central nervous system depression.

Moderate Interactions (Monitor Closely): - Serotonergic drugs (e.g., ondansetron, SSRIs): risk of serotonin syndrome. - Opioids: may enhance gastrointestinal side effects such as constipation. - Alcohol: can increase drowsiness and dizziness.